RKRashmi Kushwaha

Rashmi Kushwaha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rashmi Kushwaha has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    miR-451a is a differentially expressed blood-based microRNA in newly diagnosed CML identified by high-throughput profiling

    by Surbhi Gupta, Nitu Nigam, Abdullah H. Maad, Ninar AlJerf, S. P. Verma, Swasti Sinha, Rashmi Kushwaha, Manish Kumar Singh, Arun Kumar Trivedi, Soniya Nityanand, et al.

    Background: microRNAs (miRNAs) are emerging as promising biomarkers in hematological malignancies due to their stability in blood. This study aimed to investigate the differential expression of miRNAs in chronic myeloid leukemia (CML) and evaluate the potential of miR-451a as a candidate whole-blood miRNA marker. Methodology: We collected whole blood samples from 77 newly diagnosed CML patients before TKI therapy and 77 healthy controls. A subset of samples underwent miRNA sequencing to identify dysregulated miRNAs, and miR-451a was subsequently validated using quantitative real-time PCR (qRT-PCR). Result: The study found that miR-451a was significantly elevated in CML cases compared to controls out of all 450–500 identified miRs. Receiver operating characteristic (ROC) analysis demonstrated moderate predictive performance (AUROC = 0.655), with 76.6% sensitivity and 53.2% specificity at a defined threshold (ΔCt ≥ 1.270). Logistic regression analysis confirmed miR-451a as an independent predictor, with a 16.5% increase in disease odds for each unit (OR = 1.165, p = 0.001). These findings suggest that miR-451a may function as an independent predictor for CML and a valuable molecular marker for disease risk and progression. Conclusion: miR-451a is markedly overexpressed in the peripheral blood of patients with newly diagnosed CML and demonstrates moderate efficacy as a candidate biomarker. Its integration into a multi-marker panel may enhance diagnostic sensitivity and specificity, reinforcing its role in advancing precision medicine approaches in CML.

  • Indian Consensus Guidelines for the Diagnosis and Management of Aplastic Anemia

    by Tuphan Kanti Dolai, Kaustav Ghosh, Biju George, Shipla Roy, Rakhee Kar, Tathagata Chatterjee, Shailendra Prasad Verma, Pankaj Malhotra, Rashmi Kushwaha, Anil Irom Singh, et al.


  • Open Access

    XRRA1 acts as a molecular brake on radiation-induced DNA damage signaling and immunogenic cell death in tumor cells

    by Tanvi Qamar, Saba Ubaid, Vipin Kumar, Mohammad Kashif, Tanvi Singh, Misba Majood, Ranjana Singh, Ajay Kumar Singh, Rashmi Kushwaha, Vivek Singh

    Radiotherapy kills cancer cells by inducing DNA damage, but adaptive responses that buffer injury and limit immunogenic signaling remain incompletely understood. Although ionizing radiation can activate cytosolic DNA sensing and immunogenic cell death, the tumor-intrinsic regulators linking these processes to radioresistance are not well defined. Here, we show that XRRA1 is a stress-adaptive determinant of radioresponse identified by integrating discovery proteomics into chronic myeloid leukemia with clinical tissue validation and functional studies across multiple tumor models. In peripheral-blood proteomes, XRRA1 was quantitatively reduced in chronic myeloid leukemia yet associated with a favorable prognosis and with networks enriched for RNA regulation, apoptosis, and DNA-repair biology. In human biopsy specimens, XRRA1 protein abundance was increased in radiation-exposed tissues, and in cultured cells, ionizing radiation induced XRRA1 more strongly and persistently in normal cells than in cancer cells. Silencing XRRA1 had little effect on basal growth but markedly enhanced radiation-induced loss of viability, apoptosis, spheroid disruption, and clonogenic failure, while increasing γH2AX- and DNA-PK-associated damage signaling and linking XRRA1 to non-homologous end joining factors. XRRA1 depletion also amplified cGAS-STING-TBK1-IRF3 activation, interferon-stimulated gene expression, extracellular ATP release, and cell-surface calreticulin exposure. These findings identify XRRA1 as a molecular brake that limits the conversion of radiation-induced DNA damage into immunogenic stress responses. XRRA1, therefore, represents a candidate biomarker of radioadaptive stress and a potential target for radiosensitization and radiotherapy-immunotherapy combinations.

  • Role of IGF2BP3 as a prognostic biomarker in chronic myeloid leukemia progression and disease stratification

    by Pragati Chauhan, Saba Ubaid, Mohammad Kashif, Tanvi Singh, Gaurav Singh, Shailendra Prasad Verma, Ranjana Singh, Rashmi Kushwaha, Vivek Singh


  • Open Access

    High-Resolution Genetic Profiling of Hb J-Meerut and Other Hemoglobin Variants in the Tharu Population via HPLC and DNA Sequencing

    by Nitu Nigam, Rashmi Kushwaha, Arti Gupta, M. L. B. Bhatt, Bhupendra Singh, Sanjay Nigam, Kirti Upadhyay, Amro Amara, Sumit Rungta

    Background/Objectives: Hemoglobinopathies, including thalassemia and sickle cell disease, are among the most common inherited disorders worldwide. This study aimed to profile hemoglobin variants in the Tharu community of Lakhimpur Kheri, Uttar Pradesh, with particular focus on the rare variant Hb J-Meerut [α 120 (H3) Ala→Glu (α1)]. Methods: A cross-sectional study was conducted during a community health camp in February 2024. Peripheral blood samples were collected from 505 individuals, of which 445 were analyzed using complete blood count (CBC) and high-performance liquid chromatography (HPLC). Suspected variants were confirmed by Sanger sequencing. Results: Hemoglobinopathies were identified in nearly one-fifth of participants. The major variants detected were sickle cell trait, β-thalassemia trait, and Hb J-Meerut. Sequencing confirmed Hb J-Meerut in the majority of suspected cases. HPLC profiles showed clear differences between groups, supporting its role as a reliable screening tool. Conclusions: Community-based screening combining HPLC and sequencing provides an effective approach for identifying both common and rare hemoglobin variants. Early detection of silent carriers such as Hb J-Meerut is essential for targeted genetic counseling and preventive strategies in high-risk populations.

  • Open Access

    Long bone fracture in a child with haemophilia- surgical management under factor coverage: A case report and literature review

    by Suresh Chand, Shailendra Prasad Verma, Praseeth K. Radhakrishnan, Syed Faisal Afaque, Vikas Verma, Rashmi Kushwaha


  • Open Access

    AI-Powered Exploration of IGF2BP3 as a Prognostic Biomarker in Chronic Myeloid Leukemia Progression and Disease Stratification

    by Pragati Chauhan, Saba Ubaid, Mohammad Kashif, Tanvi Singh, Gaurav Singh, Shailendra Prasad Verma, Ranjana Singh, Rashmi Kushwaha, Vivek Singh

    Background: Chronic Myeloid Leukemia (CML) progresses through chronic, accelerated, and blast crisis phases, making disease stratification and therapeutic response prediction challenging. IGF2BP3 (Insulin-like Growth Factor 2 mRNA Binding Protein 3) has emerged as a potential prognostic biomarker due to its involvement in RNA stability and oncogenic pathways. Methods: This study employed a multi-platform approach, including immunohistochemistry (IHC), ELISA, qRT-PCR, and Western blotting, to evaluate IGF2BP3 expression in 121 CML patient samples across disease stages. Advanced artificial intelligence (ChatGPT 4.0) and statistical tools (R-Studio) were utilized to analyze correlations between IGF2BP3 levels, clinical parameters, and treatment responses. Results: IGF2BP3 expression progressively increased from the chronic to the blast crisis phase, correlating with disease severity and resistance to therapy. IHC staining intensity and serum levels of IGF2BP3 were highest in the blast crisis phase, confirmed by qRT-PCR and Western blotting. AI-powered regression analysis revealed a strong correlation between IGF2BP3 levels, P210 translocation percentages, and blast counts. Non-responders to therapy exhibited significantly elevated IGF2BP3 levels, underscoring its potential as a marker for treatment resistance. Conclusions: IGF2BP3 is a reliable biomarker for CML disease progression, therapeutic resistance, and patient stratification. Targeting IGF2BP3 may offer novel therapeutic opportunities, particularly in advanced disease stages. This study demonstrates the utility of integrating AI in biomarker research to enhance precision and actionable insights.

  • Open Access

    An Uncommon Case of Plasmodium vivax Malaria with Disseminated Intravascular Coagulation: Rare Case Report with Review of Literature

    by Anuragani Verma, Anurag Singh, Shalini Rawat, Rashmi Kushwaha

    Malaria is a severe health issue in India despite government efforts. Malaria has many complications, some of which can be life-threatening. Disseminated intravascular coagulation (DIC) is a prominent malaria complication, besides renal failure, cerebral malaria, pulmonary edema, and anemia. We report a young man with Plasmodium vivax malaria who developed septic shock due to DIC. A 25-year-old male had a fever, abdominal pain, vomiting, and nausea for 5 days. On clinical examination, the patient was in distress and had a fever of 102.6°F with a blood pressure of 86/46 mmHg. A complete blood count revealed anemia, leukocytopenia, and severe thrombocytopenia. Peripheral blood smear findings showed a P. vivax parasite in red blood cells with the presence of a few schistocytes. Further coagulation tests showed raised prothrombin, partial thromboplastin time, and d-dimer. DIC and septic shock required critical care unit admission. Conservative treatment with artesunate and lumefantrine completely cured him. This unusual case shows that P. vivax causes severe malaria and its morbid consequences. It stresses early diagnosis and treatment to prevent mortality and morbidity.

  • Open Access

    Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy

    by Akanksha Singh, Anurag Singh, Rashmi Kushwaha, Shailendra Prasad Verma, Wahid Ali, Uma Shankar Singh

    Background: Tyrosine kinase inhibitors improve chronic myeloid leukemia (CML) outcomes. Dasatinib inhibits breakpoint cluster region-Abelson 1 proto-oncogene tyrosine kinase better than imatinib in CML. T-regulatory cells prevent autoimmune diseases and aberrant immune responses by reducing oncoprotein antigen reactivity. They also reduce self-antigen-induced immune responses to maintain peripheral tolerance. In this study, T-regulatory cells in peripheral blood of chronic myeloid leukemia-chronic phase patients were measured, together with serum levels of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and transforming growth factor (TGF)-β1 at diagnosis and 3 months postdasatinib therapy. Materials and Methods: The Pathology and Clinical Haematology Departments at King George’s Medical University, Lucknow, India, conducted this prospective analytical study. Forty CML-chronic patients and 10 healthy controls were analyzed. Flow cytometry was used to determine T-regulatory cell percentage in peripheral blood mononuclear cells of newly diagnosed CML patients before and after 3 months of dasatinib treatment; ELISA was used to measure serum levels of CTLA-4 and TGF-β1. Results: T-regulatory cells, CTLA-4, and TGF-β1 significantly decreased in CML-chronic phase patients after 3 months of dasatinib therapy compared to the initial diagnosis. No significant change in T-regulatory cell, CTLA-4, or TGF-β1 percentages were seen between responders and poor responders. However, responders had a lower percentage of T-regulatory cells than suboptimal responders. Conclusions: The study concluded that dasatinib treatment improved response in CML patients with decreased Treg cells. Dasatinib reduces Treg-mediated immunological suppression, reducing CTLA-4 and TGF-β1 levels.